IFLR1000

AstraZeneca $4 billion acquisition of 55% stake in Acerta Pharma

17/12/2015
Private acquisition
Select tab

$ 4 billion

Completed

17/12/2015

Overview:

  • AstraZeneca has acquired a 55% stake in Acerta Pharma, a clinical-stage biopharmaceutical company, for $4 billion. 
  • The agreement includes an option for AstraZeneca to acquire the remaining 45% stake in Acerta Pharma for $3 billion. 
  • The deal gives the company access to blood cancer drug acalabrutinib.
  • The transaction follows the recent acquisitions by the company of ZS Pharma and the respiratory business of Takeda.

Rani Mehta - Journalist 

Jurisdictions:

United States
Netherlands
United Kingdom

Deal type:

Private acquisition

Practice area:

M&A

Industry sector:

Pharmaceuticals and life sciences

Firms:
Freshfields Bruckhaus Deringer

Party: AstraZeneca (Acquirer)

Lawyers: Hanneke Rothbarth, Jennifer Bethlehem, Julian Long, Peter Lyons, Shawn der Kinderen (retired), Thijs Flokstra

Morgan Lewis & Bockius

Party: Acerta Pharma (Seller)

Lawyers: Jedd Wider, Steven Navarro

NautaDutilh

Party: Acerta Pharma (Seller)

Lawyer: Ruud Smits

Related deals